Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eiger Biopharmaceuticals (EIGRQ) has provided an update.
William G. Kachioff is stepping down as Chief Financial Officer of Eiger BioPharmaceuticals, effective April 29, 2024, amidst the company’s ongoing Chapter 11 bankruptcy proceedings. Following his departure, Eiger BioPharmaceuticals is increasing its reliance on financial advisory firm Alvarez & Marsal, appointing its managing director Douglas Staut as Chief Restructuring Officer. Investors are warned that trading the company’s securities is highly speculative and risky, with the potential for significant or total investment losses, depending on the resolution of the bankruptcy case.
For an in-depth examination of EIGRQ stock, go to TipRanks’ Stock Analysis page.